Sabah Oney Sells 5,156 Shares of Alector Inc (NASDAQ:ALEC) Stock

Alector Inc (NASDAQ:ALEC) insider Sabah Oney sold 5,156 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $20.02, for a total transaction of $103,223.12. Following the completion of the transaction, the insider now owns 595,418 shares in the company, valued at $11,920,268.36. The transaction was disclosed in a filing with the SEC, which is available at this link.

Sabah Oney also recently made the following trade(s):

  • On Monday, December 9th, Sabah Oney sold 2,300 shares of Alector stock. The stock was sold at an average price of $20.07, for a total transaction of $46,161.00.

Shares of NASDAQ:ALEC opened at $19.55 on Wednesday. The company has a market cap of $1.37 billion and a P/E ratio of -4.23. The business has a fifty day simple moving average of $17.16 and a 200-day simple moving average of $17.53. Alector Inc has a 52 week low of $13.64 and a 52 week high of $27.00. The company has a quick ratio of 6.56, a current ratio of 6.57 and a debt-to-equity ratio of 0.19.

Alector (NASDAQ:ALEC) last released its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.07). Alector had a negative return on equity of 58.27% and a negative net margin of 378.57%. The business had revenue of $2.70 million for the quarter. Sell-side analysts expect that Alector Inc will post -1.63 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ALEC. FMR LLC acquired a new position in shares of Alector during the 1st quarter valued at about $20,862,000. Wells Fargo & Company MN lifted its holdings in shares of Alector by 89.2% during the 2nd quarter. Wells Fargo & Company MN now owns 13,650 shares of the company’s stock worth $259,000 after acquiring an additional 6,434 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Alector by 194.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 294,574 shares of the company’s stock worth $5,299,000 after acquiring an additional 194,525 shares during the period. Oppenheimer & Co. Inc. purchased a new position in shares of Alector during the 2nd quarter worth about $1,193,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Alector by 20.8% in the second quarter. Charles Schwab Investment Management Inc. now owns 56,744 shares of the company’s stock worth $1,079,000 after acquiring an additional 9,771 shares during the last quarter. Institutional investors own 50.02% of the company’s stock.

ALEC has been the subject of a number of recent research reports. Cowen reiterated a “buy” rating on shares of Alector in a report on Sunday. Zacks Investment Research raised shares of Alector from a “sell” rating to a “hold” rating in a research note on Monday, November 11th. BTIG Research began coverage on shares of Alector in a research report on Wednesday, November 27th. They set a “buy” rating and a $28.00 target price on the stock. Finally, ValuEngine lowered shares of Alector from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $27.00.

About Alector

Alector, Inc, a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease.

Further Reading: Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for Alector (NASDAQ:ALEC)

Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.